Info

Sangamo BioSciences, Inc. (Sangamo) is engaged in the development and commercialization of transcription factors for gene regulation and gene modification. Sangamo’s gene regulation and gene modification technology platform is enabled by the engineering of a class of transcription factors known as zinc finger deoxyribonucleic acid (DNA)-binding proteins (ZFPs) that can turn genes on or off and ZFP nucleases (ZFNs), proteins that enable modification of DNA sequences in various ways. The Company‘s lead candidate on its product pipeline is the SB-509, an injectable plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A gene. As of December 31, 2007, SB-509 is in three Phase II clinical trials for the treatment of diabetic neuropathy (DN). Sangamo also has preclinical development programs for spinal cord injury, stroke, traumatic brain injury, neuropathic pain and Parkinson’s disease.(Source: 10-K)